CTRI/2019/04/018795已完成2 期
Evaluation of safety and therapeutic efficacy of a siddha herbo mineral formulation Kumaara veeriya kaantha chenduram (Internal) in the treatment of azhal veluppu noi(Iron deficiency anemia)
Ayothidoss Pandithar hospital0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Hb level less than normal range
- •For male: 9-11 g/dl (normal 13-18 g/dl)
- •For female: 8-11 g/dl (normal 11.5-16.5 g/dl)
- •2.Patient willing to undergo blood investigation
排除标准
- •1.Hypertension
- •2.Presence of any associated severe systemic illness(e.g. cancer, AIDS)
- •3.Endocrine disorder(Tyroid abnormality,Diabetis melitus)
- •4.Severe cardiac illness or IHD
- •5.Inerited defects (Sickle cell anemia, thalassemia, Aplastic anaemia)
- •6.Patient not willing to give blood sample
研究者
相似试验
尚未招募
2 期
Evaluation of safety and therapeutic efficacy of siddha drug KANDAAMALAGA ILAKAM in the treatment of Iron deficiency anaemia.CTRI/2018/05/014111Ayothidoss Pandithar Hospital
已完成
4 期
Evaluation of therapeutic efficacy and safety of artesunate-amodiaquine, artemether-lumefantrine and dihydroartemisinine-piperaquine for the treatment of uncomplicated Plasmodium falciparum in Democratic Republic of CongoInfection - Studies of infection and infectious agentsMalariaACTRN12616001423404Ministry of Health534
进行中（未招募）
1 期
Study of the safety and effectiveness of drug AZD4017 at reducing pressure in the brain, in idiopathic intracranial hypertension.MedDRA version: 18.0Level: PTClassification code 10004277Term: Benign intracranial hypertensionSystem Organ Class: 10029205 - Nervous system disordersIdiopathic Intracranial HypertensionEUCTR2013-003643-31-GBniversity of Birmingham30
招募中
1 期
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes MellitusDiabetes Mellitus, Type 1Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesDiabetes MellitusType 1 diabetes mellitusRPCEC00000225Center of Molecular Immunology (CIM)40
尚未招募
2 期
VALERGEN-combination of routes- Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000298ational Center of Bioproducts (BioCen)180